Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler

Dow Jones03-25

By Connor Hart

Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive.

The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday.

Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences.

As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 25, 2025 19:35 ET (23:35 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522283777?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-26 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522283777","market":"sh","top_or_hot":-1,"title":"Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n</p>\n<p>\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n</p>\n<p>\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n</p>\n<p>\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-26 07:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n</p>\n<p>\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n</p>\n<p>\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n</p>\n<p>\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522283777","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522283777","pubTimestamp":1742945700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive.The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday.Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences.As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","BK4585":"ETF&股票定投概念","BMEA":"Biomea Fusion, Inc."},"translate_title":"Biomea Fusion任命希区柯克为临时首席执行官，接替巴特勒","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n\n\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n\n\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n\n\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 19:35 ET (23:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522283777"}